BriaCell Therapeutics stock tumbles after announcing public offering

Published 09/07/2025, 14:02
© Reuters.

Investing.com -- BriaCell Therapeutics Corp (NASDAQ:BCTX) stock plunged 22% following the announcement of a public offering that could significantly dilute existing shareholders.

The clinical-stage biotechnology company revealed plans to offer up to 6,825,938 common units on a best efforts basis. Each unit, priced at $2.93, consists of one common share and one warrant to purchase an additional common share at an exercise price of $5.25, with the warrants set to expire on April 28, 2030.

BriaCell is also offering pre-funded units as an alternative for purchasers whose acquisition would result in them owning more than 4.99% (or optionally 9.99%) of the company’s outstanding shares. These pre-funded units include a pre-funded warrant exercisable at $0.001 per share and one regular warrant, with the purchase price being $0.001 less than the common unit price.

The significant stock decline reflects investor concerns about potential share dilution. While the offering will provide capital for the company’s operations, the issuance of new shares and potential future exercise of warrants could substantially increase the number of outstanding shares.

The components of both the common units and pre-funded units will be immediately separable upon issuance and will trade separately. The offering comes as BriaCell continues development of its immunotherapy candidates for cancer treatment.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.